Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay5259 in Healthy Participants
NCT07703904Phase 1Not yet recruiting
- Sponsor
- Tianjin Hemay Biotech
- Start
- Jul 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Hemay5259 (4 arms), sponsored by Tianjin Hemay Biotech. Primary endpoints: Maximum plasma concentration, Area under the curve from time 0 to the last measurable concentration and 6 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Hemay5259
Beyond the preview
Go deeper on NCT07703904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703904.